Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy

被引：5
作者：
Bode, Axel [1 ]
Rahbar, Kambiz [1 ]
Konnert, Julia [1 ]
Boegemann, Martin [2 ]
Stegger, Lars [1 ]
机构：
[1] Univ Hosp Munster, Dept Nucl Med, Albert Schweitzer Campus 1, D-48149 Munster, Germany
[2] Univ Hosp Munster, Dept Urol, Munster, Germany
来源：
CLINICAL NUCLEAR MEDICINE | 2016年 / 41卷 / 12期
关键词：
prostate cancer; positron emission tomography; PET/CT; radium dichloride; Xofigo; PROSTATE-CANCER; DIAGNOSIS; PET/CT;
D O I：
10.1097/RLU.0000000000001374
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
A 66-year-old man with castration-resistant prostate carcinoma and multiple symptomatic bone mestastases was considered for Ra-223-dichloride (Xofigo) therapy. Staging with Ga-68-PSMA-PET/CT revealed additional extensive tumor involvement of the spine without relevant uptake in bone scintigraphy. Based on this imaging result, the patient was rescheduled for a PSMA-targeted therapy. Additional Ga-68-PSMA-PET/CT may have a considerable benefit for patients considered for Xofigo.
引用
收藏
页码：951 / 952
页数：2
相关论文
共 7 条
[1]   The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].
Afshar-Oromieh, Ali ;
Hetzheim, Henrik ;
Kratochwil, Clemens ;
Benesova, Martina ;
Eder, Matthias ;
Neels, Oliver C. ;
Eisenhut, Michael ;
Kuebler, Wolfgang ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Mier, Walter ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705
[2]   Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].
Ahmadzadehfar, Hojjat ;
Rahbar, Kambiz ;
Kuerpig, Stefan ;
Boegemann, Martin ;
Claesener, Michael ;
Eppard, Elisabeth ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Schaefers, Michael ;
Essler, Markus .
EJNMMI RESEARCH, 2015, 5 :1-8
[3]   New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy [J].
Haberkorn, Uwe ;
Eder, Matthias ;
Kopka, Klaus ;
Babich, John W. ;
Eisenhut, Michael .
CLINICAL CANCER RESEARCH, 2016, 22 (01) :9-15
[4]   Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride [J].
Pacilio, Massimiliano ;
Ventroni, Guido ;
De Vincentis, Giuseppe ;
Cassano, Bartolomeo ;
Pellegrini, Rosanna ;
Di Castro, Elisabetta ;
Frantellizzi, Viviana ;
Follacchio, Giulia Anna ;
Garkavaya, Tatiana ;
Lorenzon, Leda ;
Ialongo, Pasquale ;
Pani, Roberto ;
Mango, Lucio .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (01) :21-33
[5]   Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer [J].
Parker, C. ;
Nilsson, S. ;
Heinrich, D. ;
Helle, S. I. ;
O'Sullivan, J. M. ;
Fossa, S. D. ;
Chodacki, A. ;
Wiechno, P. ;
Logue, J. ;
Seke, M. ;
Widmark, A. ;
Johannessen, D. C. ;
Hoskin, P. ;
Bottomley, D. ;
James, N. D. ;
Solberg, A. ;
Syndikus, I. ;
Kliment, J. ;
Wedel, S. ;
Boehmer, S. ;
Dall'Oglio, M. ;
Franzen, L. ;
Coleman, R. ;
Vogelzang, N. J. ;
O'Bryan-Tear, C. G. ;
Staudacher, K. ;
Garcia-Vargas, J. ;
Shan, M. ;
Bruland, O. S. ;
Sartor, O. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (03) :213-223
[6]   68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients [J].
Sterzing, Florian ;
Kratochwil, Clemens ;
Fiedler, Hannah ;
Katayama, Sonja ;
Habl, Gregor ;
Kopka, Klaus ;
Afshar-Oromieh, Ali ;
Debus, Juergen ;
Haberkorn, Uwe ;
Giesel, Frederik L. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (01) :34-41
[7]   68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies [J].
Weineisen, Martina ;
Schottelius, Margret ;
Simecek, Jakub ;
Baum, Richard P. ;
Yildiz, Akin ;
Beykan, Seval ;
Kulkarni, Harshad R. ;
Lassmann, Michael ;
Klette, Ingo ;
Eiber, Matthias ;
Schwaiger, Markus ;
Wester, Hans-Juergen .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (08) :1169-1176
1